I wrote an article about NPSP that hit the wire today. The stock is pricing in over an 80 PE if the drug NPSP is trying to bring to market gets approved. Not much left to keep the price moving higher at this point. If the drug fails to win FDA approval a very bad day for [...]

NPS Pharmaceuticals today reported its results for the third quarter 2010. NPS reported a net loss of $15.7 million or $0.26 per diluted share for the third quarter 2010, compared to a net loss of $7.8 million or $0.16 per diluted...(read more)

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that it intends to offer and sell approximately $41,290,000 of its common stock in an underwritten public offering. The offering is subject to market conditions and there...(read more)